CAPR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Capricor Therapeutics Inc (CAPR) is not a strong buy at this moment for a beginner investor with a long-term strategy. While there are positive catalysts such as the FDA's resumed review of Deramiocel and a bullish sentiment among retail investors, the lack of strong trading signals, mixed technical indicators, and legal uncertainties make it prudent to hold off on investing until more clarity emerges.
The MACD is positive and expanding, indicating bullish momentum. The RSI is neutral at 66.052, and moving averages are converging, suggesting no clear trend. The stock is trading near its resistance level (R1: 28.543), which may limit immediate upside potential.
FDA's resumed review of Deramiocel for Duchenne muscular dystrophy with a PDUFA date set for August 22,
Retail sentiment on Stocktwits is bullish.
The stock saw an 8% increase following the FDA's decision to review Deramiocel.
Legal action against Nippon Shinyaku over the distribution agreement for Deramiocel, which could create uncertainties.
Analyst Boobalan Pachaiyappan lowered the price target from $43 to $38, citing delays in Deramiocel's U.S. launch to 2027 and removal of an $80M milestone.
The stock has shed over 7% of its value this year.
No financial data is available for analysis, making it difficult to assess the company's latest quarter performance or growth trends.
Roth Capital maintains a Buy rating but has lowered the price target from $43 to $38 due to delays in Deramiocel's U.S. launch and legal uncertainties.
